Junichiro Shimauchi

Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients.

Journal: Journal of atherosclerosis and thrombosis

Published: April 16, 2026

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Journal: Dermatology and therapy

Published: October 01, 2025

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 14, 2025

Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.

Journal: Dermatology and therapy

Published: April 02, 2024

Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.

Journal: Journal of bone and mineral metabolism

Published: June 29, 2023

Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.

Journal: Journal of bone and mineral metabolism

Published: November 04, 2021

Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.

Journal: Journal of bone and mineral metabolism

Published: June 30, 2020

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.

Journal: Journal of atherosclerosis and thrombosis

Published: May 22, 2020

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.

Journal: Journal of atherosclerosis and thrombosis

Published: November 22, 2019

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.

Journal: Circulation reports

Published: May 08, 2019

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Journal: Archives of osteoporosis

Published: March 01, 2019

Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients.

Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients.

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.

Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.

Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.

Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.

Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.

Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.

Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.

Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan.

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.